P Salehi1, I Hsu2, C G Azen3, S D Mittelman2,4, M E Geffner2,4, D Jeandron2. 1. Division of Endocrinology, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. 2. Division of Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. 3. Clinical and Translational Science Institute (CTSI), The Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA. 4. The Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
Abstract
BACKGROUND: Prader-Willi syndrome (PWS) is associated with hyperphagia and hyperghrelinemia with major morbidity because of obesity without effective medical treatment targeting hyperphagia. Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS. OBJECTIVE: The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS. METHODS: Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles. Exenatide was given using standard diabetes dosing without dietary modifications. Weight, body mass index (BMI), truncal fat, appetite and plasma acylated ghrelin were measured over 6 months. Mixed meal tolerance tests were performed at 0 and 6 months. RESULTS: Appetite scores significantly decreased from baseline (32.2 ± 8.7) after 1, 3 and 6 moths of treatment (27.5 ± 8.8, 25.4 ± 9.3, and 25.4 ± 7.2 respectively; p = 0.004). Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not. There was no significant change in ghrelin. CONCLUSIONS: This is the first longitudinal investigation of the effects of exenatide in subjects with PWS. It was effective in decreasing appetite, without change in weight or BMI in the short term. Larger, controlled, longer-term trials in patients with PWS are needed to confirm the efficacy and safety of exenatide and to evaluate whether its use might induce weight loss when given in conjunction with behavioural modification.
BACKGROUND:Prader-Willi syndrome (PWS) is associated with hyperphagia and hyperghrelinemia with major morbidity because of obesity without effective medical treatment targeting hyperphagia. Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS. OBJECTIVE: The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS. METHODS: Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles. Exenatide was given using standard diabetes dosing without dietary modifications. Weight, body mass index (BMI), truncal fat, appetite and plasma acylated ghrelin were measured over 6 months. Mixed meal tolerance tests were performed at 0 and 6 months. RESULTS: Appetite scores significantly decreased from baseline (32.2 ± 8.7) after 1, 3 and 6 moths of treatment (27.5 ± 8.8, 25.4 ± 9.3, and 25.4 ± 7.2 respectively; p = 0.004). Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not. There was no significant change in ghrelin. CONCLUSIONS: This is the first longitudinal investigation of the effects of exenatide in subjects with PWS. It was effective in decreasing appetite, without change in weight or BMI in the short term. Larger, controlled, longer-term trials in patients with PWS are needed to confirm the efficacy and safety of exenatide and to evaluate whether its use might induce weight loss when given in conjunction with behavioural modification.
Authors: David E Cummings; Karine Clement; Jonathan Q Purnell; Christian Vaisse; Karen E Foster; R Scott Frayo; Michael W Schwartz; Arnaud Basdevant; David S Weigle Journal: Nat Med Date: 2002-07 Impact factor: 53.440
Authors: Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Andrea M Haqq; I Sadaf Farooqi; Stephen O'Rahilly; Diane D Stadler; Ron G Rosenfeld; Katherine L Pratt; Stephen H LaFranchi; Jonathan Q Purnell Journal: J Clin Endocrinol Metab Date: 2003-01 Impact factor: 5.958
Authors: V A Holm; S B Cassidy; M G Butler; J M Hanchett; L R Greenswag; B Y Whitman; F Greenberg Journal: Pediatrics Date: 1993-02 Impact factor: 7.124
Authors: Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler Journal: Diabetes Obes Metab Date: 2017-07-13 Impact factor: 6.577
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Gitanjali Srivastava; Claudia K Fox; Aaron S Kelly; Ania M Jastreboff; Allen F Browne; Nancy T Browne; Janey S A Pratt; Christopher Bolling; Marc P Michalsky; Stephen Cook; Carine M Lenders; Caroline M Apovian Journal: Obesity (Silver Spring) Date: 2019-02 Impact factor: 5.002
Authors: Mila S Welling; Cornelis J de Groot; Lotte Kleinendorst; Bibian van der Voorn; Jan Steven Burgerhart; Eline S van der Valk; Mieke M van Haelst; Erica L T van den Akker; Elisabeth F C van Rossum Journal: Clin Obes Date: 2021-07-21